Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2872 Target Snapshot

Mitogen-activated protein kinase kinase kinase 9 · SINGLE PROTEIN · Homo sapiens

786Compounds
346Assays
9Approved Drugs
271.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Mitogen-activated protein kinase kinase kinase 9 shows clinical signal disease relevance led by Parkinson disease. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P80192. Start with Parkinson disease, then reuse UniProt P80192 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Parkinson disease, then reuse UniProt P80192 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
Parkinson disease

Mitogen-activated protein kinase kinase kinase 9 shows clinical signal disease relevance led by Parkinson disease. 1 linked drug remains visible in the same block.

Start review with Parkinson disease because it currently carries clinical signal support. Linked drugs include CEP-1347. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mitogen-activated protein kinase kinase kinase 9 as ChEMBL target CHEMBL2872, mapped to UniProt P80192. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mitogen-activated protein kinase kinase kinase 9
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2872
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P80192
Mitogen-activated protein kinase kinase kinase 9
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Mitogen-activated protein kinase kinase kinase 9 is the right protein anchor across sources, using UniProt P80192 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Parkinson disease is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMitogen-activated protein kinase kinase kinase 9
UniProt AccessionP80192
Component TypeProtein
Sequence Length1104 aa

Mitogen-activated protein kinase kinase kinase 9

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Mitogen-activated protein kinase kinase kinase 9, mapped to UniProt P80192. Sequence length is 1104 aa.

Mapped IDP80192
Review nameMitogen-activated protein kinase kinase kinase 9
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Mitogen-activated protein kinase kinase kinase 9 shows clinical signal disease relevance led by Parkinson disease.

Clinical signal Phase II
Parkinson disease
1 linked drug · 1 direct · 1 efficacy
Linked drugCEP-1347
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with Parkinson disease because it currently carries clinical signal support. Linked drugs include CEP-1347. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseParkinson disease
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

9
Approved
6
Phase III
8
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC50147.0
KI2.0
KD122.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 9.26 IC50 0.544 Preclinical
CHEMBL4465866 8.7 Kd 2.0 Preclinical
CHEMBL4576489 8.52 Kd 3.0 Preclinical
CHEMBL603469 8.46 Kd 3.5 Clinical
CHEMBL4116008 8.4 IC50 4.0 Clinical
CHEMBL475251 8.37 Kd 4.3 Clinical
CHEMBL388978 8.0 Kd 10.0 Preclinical
CHEMBL4218417 7.89 IC50 13.0 Preclinical
CHEMBL5397819 7.85 IC50 14.0 Preclinical
CHEMBL5436267 7.85 IC50 14.0 Preclinical
Distribution

pChEMBL Value Distribution

15
5.0
17
5.5
18
6.0
20
6.5
29
7.0
23
7.5
6
8.0
3
8.5
2
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIDOSTAURIN
CHEMBL608533
Approved 2017
BRIGATINIB
CHEMBL3545311
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
PAZOPANIB
CHEMBL477772
Approved 2009
Assay Landscape

Assay Landscape

346
Total Assays
118
Tested Compounds
2
Assay Types
Binding — 344 assays, 118 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 277 91 6.7
assay format 43 20 6.6
cell-based format 19 7 7.4
subcellular format 5 0
Functional — 2 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 2 6.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine